1999年 6月 2 9日 ,帕络阿洛图。美国食品药物管理局 (ＦＤＡ)已经认可Ａｌｚａ公司所推出的Ｄｏｘｉｌ(盐酸阿霉素脂质体注射剂 )能治疗顽固性卵巢癌。Ｄｏｘｉｌ适用于那些曾经用过当今一流的化疗方法医治过的顽固性卵巢癌患者。顽固性卵巢癌被定义为 :在治疗过程中或完成治 June 29, 1999, Palo Alto. The United States Food and Drug Administration (FDA) has recognized that Alza Corporation’s Doxil (doxorubicin liposomal injections) can treat refractory ovarian cancer. Doxil is for patients with refractory ovarian cancer who have been treated with today’s best-in-class chemotherapy. Persistent ovarian cancer is defined as: during or after treatment